CenterStar Asset Management’s AstraZeneca AZN Stock Holding History

CenterStar Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,340	Closed	-$586K	–	277
2025 Q3	$512K	Buy	+3,340	New	+$506K	0.11%	169
2025 Q2	–	Sell	-1,564	Closed	-$230K	–	229
2025 Q1	$230K	Buy	+1,564	New	+$226K	0.05%	299
2022 Q3	–	Hold	0	–	–	–	245
2022 Q1	–	Hold	0	–	–	–	633
2020 Q1	–	Hold	0	–	–	–	192

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CenterStar Asset Management's AZN Position: Q4 2025 in Review

CenterStar Asset Management sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 3,340 shares — an estimated $586K sold.

CenterStar Asset Management first reported a position in AZN in Q1 2025 and held it in 2 quarters. The position peaked at $512K in Q3 2025. 1,407 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

CenterStar Asset Management reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
CenterStar Asset Management sold 3,340 AstraZeneca shares in Q4 2025, an estimated $586K.
CenterStar Asset Management first reported a position in AstraZeneca in Q1 2025 and held it in 2 quarters.
CenterStar Asset Management's AstraZeneca position peaked at $512K in Q3 2025.
1,407 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on CenterStar Asset Management's 13F filing for Q4 2025, filed 27 Jan 2026.